LEXARIA BIOSCIENCE CORP. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
LEXARIA BIOSCIENCE CORP. (LEXX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $92.02 thousand as of 2026-02-28, per its 10-Q filed 2026-04-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-04-13
- 2026-02-28: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $92.02K.
- 2025-11-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $99.48K.
- 2025-08-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $106.82K.
- 2025-05-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $114.02K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-02-28 | $92.02K 10-Q · filed 2026-04-13 |
| 2025-11-30 | $99.48K 10-Q · filed 2026-01-13 |
| 2025-08-31 | $106.82K 10-Q · filed 2026-04-13 |
| 2025-05-31 | $114.02K 10-Q · filed 2025-07-14 |
| 2025-02-28 | $121.08K 10-Q · filed 2025-04-14 |
| 2024-11-30 | $128.03K 10-Q · filed 2025-01-10 |
| 2024-08-31 | $134.84K 10-K · filed 2025-11-28 |
| 2024-05-31 | $143.32K 10-Q · filed 2024-07-12 |
| 2024-02-29 | $150.00K 10-Q · filed 2024-04-09 |
| 2023-11-30 | $156.56K 10-Q · filed 2024-01-12 |
| 2023-08-31 | $167.45K 10-K · filed 2024-11-26 |
| 2023-05-31 | $178.13K 10-Q · filed 2023-07-14 |
| 2023-02-28 | $32.05K 10-Q · filed 2023-04-14 |
| 2022-11-30 | $42.34K 10-Q/A · filed 2023-01-18 |
| 2022-08-31 | $52.44K 10-K · filed 2023-11-20 |
| 2021-08-31 | $91.04K 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |